Diretrizes brasileiras de manejo de toxicidades imunomediadas associadas ao uso de bloqueadores de correceptores imunes

Diretrizes brasileiras de manejo de toxicidades imunomediadas associadas ao uso de bloqueadores de correceptores imunes

Nos últimos anos, assistimos à consolidação da “imunoterapia” como uma forma efetiva e viável de se tratar o câncer. Em particular, a manipulação terapêutica de moléculas envolvidas na modulação da resposta imune com o uso de anticorpos monoclonais, ou bloqueadores de correceptores imunes, viabilizo...

Full description

Saved in:

Bibliographic Details
Main Author:	Grupo de Trabalho da Sociedade Brasileira de Oncologia Clínica
Format:	Article
Language:	English
Published:	Thieme Revinter Publicações Ltda. 2017-01-01
Series:	Brazilian Journal of Oncology
Subjects:	Imunoterapia Antígeno CTLA-4 Receptor de morte celular programada 1 An-ticorpos monoclonais Immunotherapy CTLA-4 antigen Programmed cell death 1 receptor Antibodies, monoclonal
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1792178
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Występowanie polimorfizmu w pozycji 49 eksonie 1 genu CTLA-4 u dzieci z chorobą Hashimoto
by: Anna M. Kucharska, et al.
Published: (2006-09-01)

IL-1R2 promotes tumorigenesis and modulates the tumor immune microenvironment in colorectal cancer
by: Yanyan Lang, et al.
Published: (2025-08-01)

Placental growth factor exerts modulatory effects on in vitro activated T cells
by: E. A. Smetanenko, et al.
Published: (2021-01-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

Impact of COVID-19 on gene Expression of CTLA-4 and Its Potential Role in the Development of Rheumatoid Arthritis: A Post-Infection Analysis.
by: Maryam Sanguor, et al.
Published: (2025-06-01)

POTENTIAL ANALYSIS OF HERBAL ACTIVE COMPOUNDS AS IMMUNOTHERAPEUTIC AGENTS AGAINST CLTA-4 RECEPTOR THROUGH IN-SILICO
by: Darlene Nabila Zetta, et al.
Published: (2025-04-01)

Novas Estratégias em Imunoterapia com Células CAR-T em Pacientes com Leucemia Linfoblástica Aguda: Investigando a Ascensão da Terapêutica
by: Guilherme dos Santos Santos
Published: (2025-07-01)

The dual role of TIGIT in regulatory and effector T cells in chronic liver disease
by: Amber G. Bozward, et al.
Published: (2025-06-01)

Immunohistochemical expression of PD1, LAG3, and CTLA4 in diffuse large B cell lymphoma, clinicopathological correlation, and prognostic value
by: Madonna I. William, et al.
Published: (2025-06-01)

Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer
by: Bridget E. Crossman, et al.
Published: (2025-05-01)

EVALUATION OF THE CONTENT OF CD4+CD25+CD127LOW REGULATORY T CELLS AND THEIR FUNCTIONAL STATUS ACCORDING TO THE EXPRESSION OF CTLA-4 AND CD39 MOLECULES IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: G. A. Zhulai, et al.
Published: (2014-06-01)

Unraveling the role of Ctla-4 in intestinal immune homeostasis through a novel Zebrafish model of inflammatory bowel disease
by: Lulu Qin, et al.
Published: (2025-05-01)

BELATACEPT IN RENAL TRANSPLANTATION
by: A. I. Sushkov, et al.
Published: (2013-03-01)

Polimorfizm gena CTLA4 (49A/G) v russkoy populyatsii u bol'nykh sakharnym diabetom 1 tipa i zdorovykh donorov
by: D D Abramov, et al.
Published: (2007-09-01)

Enhanced Immune Response Against Echinococcus Granulosus Through a CTLA-4/B7 Affinity-Based Vaccine
by: Yuejie Zhu, et al.
Published: (2024-12-01)

Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer
by: Jiawei Guan, et al.
Published: (2023-12-01)

Local T-Cell Dysregulation and Immune Checkpoint Expression in Human Papillomavirus-Mediated Recurrent Respiratory Papillomatosis
by: Hans N. C. Eckel, et al.
Published: (2025-06-01)

Overexpression of CTLA-4 and fibronectin, and lower expression of CD137 (4-1BB) is associated with brain metastasis of primary skin melanomas. An analysis of local immune response by digital spatial profiling
by: Shiva Najjary, et al.
Published: (2025-06-01)

The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease
by: Fatimah Eliana, et al.
Published: (2017-11-01)

The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease
by: Fatimah Eliana, et al.
Published: (2017-11-01)

Prognostic value of the levels of CTLA-4 and its ligand B7.2 in patients with colorectal cancer
by: A. V. Chetveryakov, et al.
Published: (2023-07-01)

The immune exhaustion paradox: activated functionality during chronic bacterial infections
by: María L Ruiz-de la Cruz, et al.
Published: (2024-12-01)

Immunotherapy as an Innovative Treatment for Non-Small Cell Lung Cancer – A Comprehensive Literature Review
by: Aneta Rasińska, et al.
Published: (2025-05-01)

CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis
by: Minjun Ahn, et al.
Published: (2025-05-01)

Challenges in subtyping disease entities of thyroid dysfunction following combined immune checkpoint inhibitor therapy: a case report
by: Marco Juul Thomsen, et al.
Published: (2025-07-01)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023-12-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
by: Yaofei Jiang, et al.
Published: (2025-03-01)

Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01)

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
by: Yoichiro Narikawa, et al.
Published: (2025-08-01)

Challenges and advances of immune checkpoint therapy
by: Lingyu Li, et al.
Published: (2024-12-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer
by: Fang Zhou, et al.
Published: (2025-06-01)

The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency
by: Prabha Chandrasekaran, et al.
Published: (2025-02-01)

Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01)

Immunological barriers to immunotherapy in primary and metastatic breast cancer
by: Mara De Martino, et al.
Published: (2021-06-01)

Enhancing Tumor Immunity with IL-12 and PD-1 Blockade: A Strategy for Inducing Robust Central Memory T Cell Responses in Resistant Cancer Model
by: Fentian Chen, et al.
Published: (2024-11-01)

Efficacy of CLT4A variants as immunoregulatory molecules among Vitiligo patients in Saudi Arabia
by: Amal F. Alshammary, et al.
Published: (2025-02-01)

Polimorfizm genov HLA klassa II i CTLA4 zdorovykh buryat i bol'nykh sakharnym diabetom 1 tipa v Buryatskoy Respublike
by: Ivan Ivanovich Dedov, et al.
Published: (2006-03-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab
by: Hifaa Al Remawi, et al.
Published: (2025-12-01)

ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES
by: E. L. Nasonov
Published: (2015-10-01)